ADAM15 and rheumatoid arthritis: We found that ADAM15 siRNA-treated HUVECs showed decreased migration compared with control siRNA-treated cells towards RA synovial fluids (4.1 ± 0.7 and 1.9 ± 0.1, p < 0.05, Figure 3B).